Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme receives "complete response" letter for Clolar

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA has issued a "complete response" letter for Genzyme's sNDA for use of Clolar (clofarabine) in previously untreated older adult patients with acute myeloid leukemia, the firm announced Oct. 6. FDA's Oncologic Drugs Advisory Committee voted in September that data from a randomized, controlled trial was necessary to establish safety and efficacy in the proposed adult AML indication (1"The Pink Sheet," Sept. 7, 2009). FDA's letter recommends Genzyme conduct such a trial. Drug sponsors seeking approval for elderly AML have argued that randomized trials are difficult to conduct in the setting, and Genzyme sought approval based on a single-arm trial. The company is already conducting a randomized, placebo-controlled Phase III trial of clofarabine plus cytarabine in relapsed and refractory AML patients over 55, with results expected in 2011. Genzyme plans to meet with FDA to discuss whether the additional study may satisfy regulatory requirements. Clolar is already approved for pediatric ALL

You may also be interested in...



No Regulatory Slack For Tough Supplemental Indications, Pazdur Tells ODAC

FDA may hold approval of supplemental indications to a higher standard of evidence than what can feasibly be obtained since the drugs are already available to treat patients in an off-label setting, FDA Office of Drug Oncology Products Director Richard Pazdur indicated at a Sept. 1 advisory committee meeting

Speedy Approval Of Gilead’s Veklury Sets Stage For Pediatric Expansion, Dosing Refinement

US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.

Adolescents In COVID-19 Vaccine Trials: As Pfizer Starts Dosing, US FDA Encouraging Other Sponsors

But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.

Topics

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel